Conditions: Pulmonary Arterial Hypertension Pulmonary Hypertension
Keywords: Sitaxsentan endothelin receptor antagonist
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 183
Healthy volunteers: no

Brief summary:
This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.

Detailed description:

Arms:
arm 1: Monotherapy arm 2: Monotherapy

Interventions: intervention 1: Sitaxsentan intervention 2: Placebo
Intervention descriptions: intervention 1: Sitaxsentan = 100 mg tablet administered orally, once daily intervention 2: Sitaxsentan Placebo = 1 tablet administered orally, once daily

Protocol document: